Award
NIH Reporter #11408899
Novel Nucleotide HNF4α Transcriptional Modulation for End Stage Liver Disease with Cirrhosis
Recipient
MASTERSWITCH, INC.
Award Amount
$1,189,285.00
Ceiling
$1,189,285.00
Awarded
September 07, 2026
Identifier
11408899
Award for developing a nucleotide-lipid nanoparticle therapy targeting end-stage liver disease with cirrhosis, including therapeutic dose identification and manufacturing protocol development, funded by NIDDK, NIH.
Description
The project involves developing a nucleotide-lipid nanoparticle (LNP) therapy to treat end-stage liver disease caused by cirrhosis. The project aims to finalize the nucleotide-LNP construct, identify therapeutic doses, and develop manufacturing protocols. It is part of a Phase II clinical trial development funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH.